S&P 500   4,279.58 (+0.14%)
DOW   33,583.32 (-0.11%)
QQQ   354.89 (+0.19%)
AAPL   170.86 (-0.64%)
MSFT   311.08 (-0.34%)
META   299.37 (+0.14%)
GOOGL   129.31 (+0.58%)
AMZN   124.91 (-0.85%)
TSLA   243.31 (-0.33%)
NVDA   422.63 (+0.84%)
NIO   8.38 (-0.36%)
BABA   85.93 (+0.02%)
AMD   97.78 (+1.90%)
T   14.96 (-0.40%)
F   12.37 (-0.48%)
MU   67.89 (-0.07%)
CGC   0.98 (+6.76%)
GE   110.82 (+0.81%)
DIS   80.37 (+0.40%)
AMC   7.90 (-0.13%)
PFE   32.11 (-0.90%)
PYPL   58.71 (-0.37%)
NFLX   381.19 (+0.51%)
S&P 500   4,279.58 (+0.14%)
DOW   33,583.32 (-0.11%)
QQQ   354.89 (+0.19%)
AAPL   170.86 (-0.64%)
MSFT   311.08 (-0.34%)
META   299.37 (+0.14%)
GOOGL   129.31 (+0.58%)
AMZN   124.91 (-0.85%)
TSLA   243.31 (-0.33%)
NVDA   422.63 (+0.84%)
NIO   8.38 (-0.36%)
BABA   85.93 (+0.02%)
AMD   97.78 (+1.90%)
T   14.96 (-0.40%)
F   12.37 (-0.48%)
MU   67.89 (-0.07%)
CGC   0.98 (+6.76%)
GE   110.82 (+0.81%)
DIS   80.37 (+0.40%)
AMC   7.90 (-0.13%)
PFE   32.11 (-0.90%)
PYPL   58.71 (-0.37%)
NFLX   381.19 (+0.51%)
S&P 500   4,279.58 (+0.14%)
DOW   33,583.32 (-0.11%)
QQQ   354.89 (+0.19%)
AAPL   170.86 (-0.64%)
MSFT   311.08 (-0.34%)
META   299.37 (+0.14%)
GOOGL   129.31 (+0.58%)
AMZN   124.91 (-0.85%)
TSLA   243.31 (-0.33%)
NVDA   422.63 (+0.84%)
NIO   8.38 (-0.36%)
BABA   85.93 (+0.02%)
AMD   97.78 (+1.90%)
T   14.96 (-0.40%)
F   12.37 (-0.48%)
MU   67.89 (-0.07%)
CGC   0.98 (+6.76%)
GE   110.82 (+0.81%)
DIS   80.37 (+0.40%)
AMC   7.90 (-0.13%)
PFE   32.11 (-0.90%)
PYPL   58.71 (-0.37%)
NFLX   381.19 (+0.51%)
S&P 500   4,279.58 (+0.14%)
DOW   33,583.32 (-0.11%)
QQQ   354.89 (+0.19%)
AAPL   170.86 (-0.64%)
MSFT   311.08 (-0.34%)
META   299.37 (+0.14%)
GOOGL   129.31 (+0.58%)
AMZN   124.91 (-0.85%)
TSLA   243.31 (-0.33%)
NVDA   422.63 (+0.84%)
NIO   8.38 (-0.36%)
BABA   85.93 (+0.02%)
AMD   97.78 (+1.90%)
T   14.96 (-0.40%)
F   12.37 (-0.48%)
MU   67.89 (-0.07%)
CGC   0.98 (+6.76%)
GE   110.82 (+0.81%)
DIS   80.37 (+0.40%)
AMC   7.90 (-0.13%)
PFE   32.11 (-0.90%)
PYPL   58.71 (-0.37%)
NFLX   381.19 (+0.51%)
OTCMKTS:VYNT

Vyant Bio (VYNT) Stock Forecast, Price & News

$0.16
+0.01 (+6.62%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.16
$0.19
50-Day Range
$0.14
$0.28
52-Week Range
$0.14
$3.00
Volume
73,360 shs
Average Volume
37,615 shs
Market Capitalization
$1.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Vyant Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
3,005.6% Upside
$5.00 Price Target
Short Interest
Healthy
0.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.55mentions of Vyant Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars


VYNT stock logo

About Vyant Bio (OTCMKTS:VYNT) Stock

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

VYNT Price History

VYNT Stock News Headlines

Vyant Bio (OTCMKTS:VYNT) Shares Up 7.3%
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
AI Can Find Cancer’s Origin: Study
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Vyant Bio to pursue listing on OTC Pink Open Market
8-K: Vyant Bio, Inc.
See More Headlines
Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Company Calendar

Last Earnings
11/11/2021
Today
9/27/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:VYNT
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+3,005.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-22,690,000.00
Net Margins
-3,474.81%
Pretax Margin
-3,281.86%

Debt

Sales & Book Value

Annual Sales
$670,000.00
Book Value
$1.69 per share

Miscellaneous

Free Float
5,724,000
Market Cap
$1.02 million
Optionable
Not Optionable
Beta
1.79
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Andrew D.C. LaFrence CPA (Age 60)
    CPA, Pres, CEO & CFO
    Comp: $407.4k
  • Mr. Yung-Ping Yeh M.B.A.Mr. Yung-Ping Yeh M.B.A. (Age 47)
    M.S., P.M.P., Co-Founder & Director
    Comp: $22.5k













VYNT Stock - Frequently Asked Questions

Should I buy or sell Vyant Bio stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VYNT shares.
View VYNT analyst ratings
or view top-rated stocks.

What is Vyant Bio's stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month price objectives for Vyant Bio's shares. Their VYNT share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 3,005.6% from the stock's current price.
View analysts price targets for VYNT
or view top-rated stocks among Wall Street analysts.

How have VYNT shares performed in 2023?

Vyant Bio's stock was trading at $0.7025 at the start of the year. Since then, VYNT shares have decreased by 77.1% and is now trading at $0.1610.
View the best growth stocks for 2023 here
.

When is Vyant Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our VYNT earnings forecast
.

How were Vyant Bio's earnings last quarter?

Vyant Bio, Inc. (OTCMKTS:VYNT) posted its earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.75). The firm had revenue of $1.51 million for the quarter, compared to analysts' expectations of $2.19 million. Vyant Bio had a negative trailing twelve-month return on equity of 151.82% and a negative net margin of 3,474.81%. During the same quarter in the previous year, the firm earned ($2.90) earnings per share.

When did Vyant Bio's stock split?

Shares of Vyant Bio reverse split on the morning of Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What is Vyant Bio's stock symbol?

Vyant Bio trades on the OTCMKTS under the ticker symbol "VYNT."

How do I buy shares of Vyant Bio?

Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vyant Bio's stock price today?

One share of VYNT stock can currently be purchased for approximately $0.16.

How much money does Vyant Bio make?

Vyant Bio (OTCMKTS:VYNT) has a market capitalization of $1.02 million and generates $670,000.00 in revenue each year.

How can I contact Vyant Bio?

Vyant Bio's mailing address is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. The official website for the company is stemonix.com. The company can be reached via phone at (201) 479-1357, via email at jzimmons@zimmonsic.com, or via fax at 201-528-9201.

This page (OTCMKTS:VYNT) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -